Rare Disease Report

Jennifer Payne

Jennifer’s valuable and insightful perspectives as a federal employee, public health servant, and adult with PKU, mother of 3 nonPKU children, advocate and primary stakeholder are complimented by her passion and professional experiences in pharmacy and public policy. Jennifer’s experiences encompass numerous written avocations, testimony at FDA public meetings, as well as lobby efforts on Capitol Hill, teaching, and participation in various orphan disease summits, conferences, campaigns, and local and global observances of relevance to patients with rare disorders.
October 30, 2017
This month marks the 224th anniversary of America’s first major epidemic that took place in Philadelphia, PA in 1793.
March 12, 2017
This article submission is in response to recent publication in the Food and Drug Law Journal on medical food best practices1 by principal author, Bruce Burnett and lead of trade association - the Nutrition and Medical Food Coalition (NMFC).
January 15, 2017
While the VA prides itself as being on the forefront of knowledge and discovery — one area of research that does remain in an existential vacuum is the category of FDA regulated medical foods
September 08, 2016
it is only in recent years that scientific milestones have come to harness the potential of symbiotic relationships between microbiota and the human host.
May 15, 2016
In balancing holistic needs for patients with rare disease, an atypical case scenario is offered to illustrate the role of faith in the art of healing.
May 15, 2016
Burkitt's lymphoma is considered a "therapeutic emergency8" among medical establishment and the intensive, complex chemotherapy cocktails put patients at risk for an array of secondary complications
March 09, 2016
In memorandum, Jerome E. Weiland 2/21/45 — 12/22/15
November 30, 2015
December 3 Marks National Observance for PKU Awareness in the United States.
November 27, 2015
Today, the echoes of DESI still reverberate.
October 15, 2015
the government has found a favored policy option in affording incentive to those who engage in a game of regulatory risk through restricted competition.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.